Pharmafile Logo
Pharmafocus logo
Advanced Search

avelumab

Showing 11 posts of 11 posts found.

EMA has validated Merck and Pfizer’s MAA for avelumab

November 1, 2016
Manufacturing and Production, Sales and Marketing EMA, Merck KGaA, Pfizer, avelumab

The European Medicines Agency has validated the Marketing Authorisation Application for avelumab for the proposed indication of metastatic Merkel cell …

News
transgene

Transgene announce key partnership with Merck KGaA and Pfizer

October 12, 2016
Research and Development Cancer, France, Merck Group, Pfizer, Transgene, avelumab, head, neck

Transgene, a company that designs and developed targeted immunotherapies to treat cancer and infectious diseases, has announced a collaboration agreement …

News
clinical_trial_3

Merck and Pfizer begin Phase III trials for avelumab in ovarian cancer

July 6, 2016
Research and Development Merck, Pfizer, avelumab

Merck (KGaA, Darmstadt) and Pfizer (NYSE: PFE) have announced the initiation of the first Phase III study of investigational compound, …

News
test_results

Pivotal avelumab data in Merkel cell carcinoma presented at ASCO

June 6, 2016
Manufacturing and Production, Research and Development ASCO, Merck, Pfizer, avelumab, merkel cell carcinoma

New data presented at the American Society of Clinical Oncology’s annual general meeting has shown that avelumab, an investigational anti-PD-L1 …

News
trials

Phase III trial initiated in Merck and Pfizer partnership for renal cell carcinoma drug

April 6, 2016
Research and Development Merck, Pfizer, avelumab, carcinoma, inlyta, javelin, partnership, phase III, renal

The first patient has been treated in the Phase III clinical trial, which sees Merck (ETR: MRK) and Pfizer (NYSE: …

News
Ovarian cancer

Pfizer, Merck and Syndax in ovarian cancer trial collaboration

January 5, 2016
Manufacturing and Production, Research and Development Merck, Pfizer, Syndax Pharmaceuticals, avelumab, entinostat, ovarian cancer

Pfizer, Merck and Syndax Pharmaceuticals have announced a collaboration to test avelumab, in combination with Syndax’s entinostat, in patients with …

News
CT scan

Merck and Pfizer kick off Phase III avelumab cancer trials

December 23, 2015
Research and Development Merck, Pfizer, avelumab, ovarian cancer

Merck and Pfizer have announced the opening of trial sites for an international Phase III study of avelumab in patients …

News
Merck researcher

Merck/Pfizer Alliance to collaborate on late-stage cancer trials

December 10, 2015
Research and Development Merck, Pfizer, avelumab, collaboration, gastric cancer, oncology, partnership, stomach cancer

Merck and Pfizer are partnering to run two Phase III trials of avelumab, an immuno-oncology treatment the companies hope to …

News
nsclc_merck_pfizer

Merck and Pfizer begin new Phase III avelumab trial in lung cancer

November 5, 2015
Medical Communications, Research and Development Merck, Pfizer, avelumab, lung cancer, non-small cell lung cancer

Merck and Pfizer have commenced an international Phase III study of the investigational cancer immunotherapy avelumab in patients with non-small …

News

Merck KGaA reveals ASCO plans

May 15, 2015
Sales and Marketing ASCO, Merck, Merck KGaA, Merck Serono, avelumab

Merck KGaA is the latest company to announce its slate for this year’s ASCO conference, and like other firms it …

News
Pfizer image

Merck KGaA and Pfizer alliance begins lung cancer study

April 21, 2015
Research and Development, Sales and Marketing Merck KGaA, Pfizer, avelumab, keytruda, oncology, opdivo

Merck KGaA and Pfizer have enrolled and treated the first patient in a late-stage study of their anti-PD1 cancer immunotherapy …

News

Latest content

Regeneron and Mammoth Biosciences announce CRISPR collaboration

April 26, 2024

ANGLE signs commercial agreement with AstraZeneca

April 26, 2024

Prism BioLab and Ono Pharmaceutical enter joint research and licensing agreement

April 25, 2024

Ascendis Pharma’s Yorvipath approved by MHRA for hypoparathyroidism treatment

April 25, 2024

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024